이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Lyra Therapeutics 대차 대조표 상태

재무 상태 기준 확인 4/6

Lyra Therapeutics 의 총 주주 지분은 $31.0M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $94.6M 및 $63.6M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$67.50m
주식	US$30.98m
총 부채	US$63.61m
총 자산	US$94.58m

최근 재무 상태 업데이트

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30

Recent updates

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11

Lyra Therapeutics down 19% underwhelming data from lead program

Dec 07

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

Nov 24

재무 상태 분석

단기부채: LYRA 의 단기 자산 ( $69.4M )이 단기 부채( $19.3M ).

장기 부채: LYRA 의 단기 자산( $69.4M )이 장기 부채( $44.3M ).

부채 대 자본 내역 및 분석

부채 수준: LYRA 부채가 없습니다.

부채 감소: LYRA 는) 부채 대 자기자본 비율이 10.7% 였던 5년 전과 비교하여 부채가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: LYRA 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 34.9 %의 역사적 비율로 계속 감소할 경우 LYRA 의 현금 활주로는 1년 미만입니다.

Lyra Therapeutics 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Lyra Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Lyra Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Recent updates

Lyra Therapeutics, Inc. Announces Impairment of Property and Equipment for the Quarter Ended June 30, 2024

Lyra Therapeutics, Inc. Announces Impairment of Property and Equipment for the Quarter Ended June 30, 2024

Lyra Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Lyra Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Price target decreased by 8.3% to US$11.00

Lyra Therapeutics, Inc. Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Price target decreased by 8.3% to US$11.00

Consensus revenue estimates increase by 14%, EPS downgraded

New major risk - Financial position

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lyra Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Executive Chairman recently bought US$74k worth of stock

Consensus revenue estimates increase by 17%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lyra Therapeutics, Inc Announces Appointment of Ronan O’Brien as Chief Legal Officer

Price target increased by 15% to US$12.20

Lyra Therapeutics Announces Positive Topline Results from Beacon Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis in Patients with Prior Ethmoid Sinus Surgery

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 24%

Consensus EPS estimates upgraded to US$1.66 loss

Lyra Therapeutics, Inc. announced that it expects to receive $44.11725 million in funding

Consensus revenue estimates increase by 92%, EPS downgraded

Now 23% undervalued after recent price drop

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

High number of new directors

Lyra Therapeutics Inc. Advances Phase 2 Beacon Clinical Trial of Lyr-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

Lyra Therapeutics, Inc. Announces New LYR-210 data analyses from the Phase 2 LANTERN study

Lyra Therapeutics Announces First Patient Enrolled in Pivotal Enlighten II Clinical Trial of Lyr-210 in Chronic Rhinosinusitis Patients

Consensus revenue estimates fall by 21%

Consensus revenue estimates increase by 17%

Lyra Therapeutics Announces Appointment of Richard Nieman, Md, as Chief Medical Officer, Effective July 11, 2022

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Lyra Therapeutics, Inc.(NasdaqGM:LYRA) dropped from Russell Microcap Value Index

Price target decreased to US$20.67

Lyra Therapeutics: Progress In The Clinic

Consensus forecasts updated

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

High number of new directors

Lyra Therapeutics, Inc. Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

A First Look At Lyra Therapeutics

Lyra Therapeutics, Inc. announced that it has received $100.494971 million in funding from a group of investors

Lyra Therapeutics, Inc. announced that it expects to receive $100.494971 million in funding

High number of new directors

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Lyra Therapeutics, Inc. Appoints Jim Tobin to Board of Directors

High number of new directors

Lyra Therapeutics, Inc. Announces Enrollment of First Patient in Phase 3 ENLIGHTEN I Clinical Trial of LYR-210 in Adult Patients with Chronic Rhinosinusitis

Lyra Therapeutics Appoints Harlan W. Waksal as Executive Chairman

Lyra Therapeutics, Inc. Announces Initiation of LYR-210 Pivotal Phase 3 Enlighten Program in Surgically Naïve Chronic Rhinosinusitis Patients

Price target decreased to US$24.00

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Lyra Therapeutics, Inc. Announces Publication of Positive Lantern Results in the International Forum of Allergy & Rhinology

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo Technology Platform in the American Journal of Rhinology & Allergy

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis

Lyra Therapeutics, Inc.(NasdaqGM:LYRA) dropped from Russell 3000E Value Index

Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis

Price target decreased to US$26.75

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

Lyra Therapeutics, Inc., Annual General Meeting, May 26, 2021

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Lyra Therapeutics, Inc. to Report Q4, 2020 Results on Mar 09, 2021

Lyra Therapeutics Announces Appointment of Robert Kern as Chief Medical Officer

New 90-day high: US$14.77